Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.

Date publication

mars 2026

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ZANETTA Sylvie

Tous les auteurs :
Hadoux J, Hernando J, Wong KH, Do Cao C, Lasolle H, Buffet C, Benisvy D, Illouz F, Schneegans O, Varnier R, Drui D, Zanetta S, Hescot S, Muller M, Nascimento C, Roudaut N, Khanal M, Zheng S, Li X, Singh R, Tian W, Afonso AS, Houot B, Borget I, Segall G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41780123

Résumé

The single-arm phase I/II LIBRETTO-001 trial demonstrated durable efficacy with selpercatinib in patients with rearranged during transfection (RET)-mutation-positive medullary thyroid cancer (MTC). RECALIB-RET compared effectiveness outcomes using a real-world external control (EC) arm of patients with RET-mutation-positive MTC treated with standard of care (SoC) versus selpercatinib (LIBRETTO-001).

Mots clés

LIBRETTO-001, RET mutation, medullary thyroid cancer, multikinase inhibitors, real-world external control arm, selpercatinib

Référence

ESMO Open. 2026 03 3;11(3):106083